Harpoon Therapeutics (NASDAQ:HARP) versus Taysha Gene Therapies (NASDAQ:TSHA) Head to Head Comparison

Harpoon Therapeutics (NASDAQ:HARP) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Valuation & Earnings

This table compares Harpoon Therapeutics and Taysha Gene Therapies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harpoon Therapeutics $5.78 million 106.15 -$55.57 million ($2.55) -7.42
Taysha Gene Therapies N/A N/A N/A N/A N/A

Taysha Gene Therapies has lower revenue, but higher earnings than Harpoon Therapeutics.

Profitability

This table compares Harpoon Therapeutics and Taysha Gene Therapies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harpoon Therapeutics -434.74% -68.32% -29.45%
Taysha Gene Therapies N/A N/A N/A

Insider and Institutional Ownership

79.0% of Harpoon Therapeutics shares are held by institutional investors. Comparatively, 42.2% of Taysha Gene Therapies shares are held by institutional investors. 34.9% of Harpoon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Harpoon Therapeutics and Taysha Gene Therapies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harpoon Therapeutics 0 0 8 0 3.00
Taysha Gene Therapies 0 0 6 0 3.00

Harpoon Therapeutics presently has a consensus price target of $31.75, indicating a potential upside of 67.72%. Taysha Gene Therapies has a consensus price target of $43.92, indicating a potential upside of 92.45%. Given Taysha Gene Therapies’ higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Harpoon Therapeutics.

Harpoon Therapeutics Company Profile

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.